Key Takeaways
- • Novo Nordisk ADR (NVO) closed at $38.64 on October 9, 2026, up $0.46 (+1.20%), per Yahoo Finance quote data, with after-hours trading at $38.60.
- • The stock trades near the low end of its 52-week range of $35.12 to $64.16, and one publisher source describes it as down more than 70% from its 2024 peak.
- • Trailing P/E is 9.45 and forward dividend yield is 4.65%, with the next earnings date set for November 4, 2026.
- • Morgan Stanley downgraded NVO to Underweight on September 11, 2026, maintaining a $40 price target; the 1-year target estimate averages $46.09.
- • Trading remained tied to Wegovy and Ozempic demand, according to publisher context, with volume of 9.38M shares versus a 12.69M average.
Summary
Novo Nordisk A/S American Depositary Receipts (NVO) closed at $38.64 on October 9, 2026, rising $0.46, or 1.20%, according to Yahoo Finance market data. The day's range was $38.06 to $68.68 (reported as 38.06 to 38.68), and volume reached about 9.38 million shares against an average of 12.69 million. After-hours trading was marginally lower at $38.60.
The stock remains near the bottom of its 52-week range of $35.12 to $64.16. Several quote pages describe NVO as trading near multi-year lows, with one noting it is down more than 70% from its 2024 level. Intraday quotes from other publishers on the same date ranged from roughly $37.15 to $38.60, and Cboe data cited options sentiment as mixed with light volume of about 24,000 contracts.
Valuation metrics reported by Yahoo Finance show a trailing P/E of 9.45, trailing EPS of $4.09, and a market capitalization of about $170.6 billion. Trailing revenue was $329.43 billion, with a 35.35% profit margin and net income of $116.44 billion. The forward dividend is $1.80, a 4.65% yield, and the most recent ex-dividend date was August 17, 2026. Total cash stood at $44.98 billion and debt-to-equity at 63.33%.
On the analyst side, Morgan Stanley downgraded the stock to Underweight on September 11, 2026, maintaining a $40 price target. The average one-year target estimate cited is $46.09. The company's next earnings report is scheduled for November 4, 2026.
Publisher context ties the stock's trading to continued demand for its Wegovy and Ozempic franchises. The source material available for this story consists largely of quote pages and market data snapshots, so no company-specific operational announcements from October 9, 2026 could be confirmed.
The stock remains near the bottom of its 52-week range of $35.12 to $64.16. Several quote pages describe NVO as trading near multi-year lows, with one noting it is down more than 70% from its 2024 level. Intraday quotes from other publishers on the same date ranged from roughly $37.15 to $38.60, and Cboe data cited options sentiment as mixed with light volume of about 24,000 contracts.
Valuation metrics reported by Yahoo Finance show a trailing P/E of 9.45, trailing EPS of $4.09, and a market capitalization of about $170.6 billion. Trailing revenue was $329.43 billion, with a 35.35% profit margin and net income of $116.44 billion. The forward dividend is $1.80, a 4.65% yield, and the most recent ex-dividend date was August 17, 2026. Total cash stood at $44.98 billion and debt-to-equity at 63.33%.
On the analyst side, Morgan Stanley downgraded the stock to Underweight on September 11, 2026, maintaining a $40 price target. The average one-year target estimate cited is $46.09. The company's next earnings report is scheduled for November 4, 2026.
Publisher context ties the stock's trading to continued demand for its Wegovy and Ozempic franchises. The source material available for this story consists largely of quote pages and market data snapshots, so no company-specific operational announcements from October 9, 2026 could be confirmed.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.